A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients
Clinical trial NCT03560739 · COMPLETED
Trial details
- NCT number
- NCT03560739
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-11
- Primary completion
- 2019-08-26
- Enrollment
- 284
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.